Vaccine maker, Novavax, announced Monday that its experimental COVID-19 vaccine is more than 90% effective against the disease, symptoms, and other variants.
Though the demand for COVID-19 shot in the U.S. have slowed to a crawl, the need for more vaccines around the world remains a focus point. This after more than half of the U.S. population has had at least one vaccine dose, while less than 1 percent of the population of developing world countries have had one shot.
The company says it plans to seek authorization to produce up to 100 million doses in the U.S., Europe and other parts of the world by the end of September.
The Novavax vaccine is easy to store and transport, which makes it ideal for distributing long distances.
